Patent · US Active

Cladribine regimen for treating multiple sclerosis

US10555913B2 · kind B2 · utility

2Cited by

22References

18Claims

0Family size

Assignee

MERCK SERONO SA · CH

Inventors

H. James Brentzel, Jr. · Marshfield, US
Maria Lopez-Bresnahan · Lincoln, US
Nazih Ammoury · Ferney-Voltaire, FR

Key dates

Filing date	Mar 22, 2018
Grant date	Feb 11, 2020
Priority date	—
Expiry date	Mar 22, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.